Company Overview:
Contact: Kevin Kleinfeld
Location: San Diego, CA
Email: kkleinfeild@tpims.org
Tel: 858-455-3776
Website: http://www.ffasciences.com/

Company Profile
Industry Sector: In Vitro Diagnostics (Blood Tests)
Company Profile: FFA Sciences is using high-throughput protein engineering to develop rapid easy to use and non-invasive diagnostics for human disease.

Target Market(s):
Hyperbilirubinemia (jaundice) - common condition in newborn babies that can lead to neurological damage.
Fatty liver Disease (NAFLD) - One of the fastest growing diseases in the U.S. – can lead to cirrhosis of the liver (requiring transplant) – occurs in children.
Acute Coronary Syndromes (ACS) – the largest cause of death in first world countries – desperate need for a simple blood test.
Stroke: No Accurate Blood Tests & therapies are underutilized as result.
Seeking: Alliance w/ large diagnostics Co. to manufacture & distribute.

Key Value Drivers
Technology: The Company has developed a technology platform to molecular probes for unbound Metabolites (METu) in blood samples. The unbound metabolites are the physiologically active fraction and therefore most important. Our results indicate that the pattern of these unbound MET is disease-specific. The METu pattern generated by a particular disease provides a highly sensitive and specific diagnosis of the disease. The technology uses only a drop of blood and is complete within seconds.

Competitive Advantage:

<table>
<thead>
<tr>
<th>Key Attribute</th>
<th>FFA Sciences Test</th>
<th>Arrows Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ease of Use</td>
<td>Easy – single step</td>
<td>Difficult – multiple steps</td>
</tr>
<tr>
<td>Accuracy</td>
<td>CV &lt; 5%</td>
<td>CV as high as 30%</td>
</tr>
<tr>
<td>Speed</td>
<td>1 Minute</td>
<td>15-20 Minutes</td>
</tr>
<tr>
<td>Price</td>
<td>$20</td>
<td>$70</td>
</tr>
</tbody>
</table>

Product Pipeline
Indication 2010 2011 2012 2013
Bilirubin
NAFLD
Stroke
ACS

Trials currently underway: Bilirubin (Q:3 2010), NAFLD (Q:3 2011) – expect 510K
Trials to start in 2010: Stroke & ACS – will require PMA submissions

Management
Alan Kleinfeld, Ph.D. – CEO (Member Torrey Pines Institute, Harvard University)
   Inventor of Technology – Over 25 years exp w fluorescent probes
Richard Houghten – Chairman- President Torrey Pines Institute (CA & FL)
   Founded 3 Co’s – 1 IPO & 1 Acquisition
Kevin Kleinfeld- Vice President (Partner ICM Capital Management-private equity)
   Involved in > 30 M&A transactions valued at > $3 billion
Andrew Huber, Ph.D. – Director Protein Chemistry (Structural Genomics)
   8 years exp w/ FFA & over 15 yrs exp with protein chemistry
Baolong Zhu, Ph.D. - Director of Molecular Biology (Dow AgroSciences)
   7 years exp w/ FFA & over 20 yrs exp with molecular biology
Thomas Kwan, Ph.D. – Director Biophysics (Stanford U)
   7 years exp w/ FFA & expert in polymer chemistry for testing device design

Scientific Advisory Board:
Anthony DeMaria M.D. – Chief of Cardiology UCSD
Jesse Adams – M.D. – Professor of Medicine, Jewish Hospital Louisville
Brian Gibler – M.D. Chief of Emergency Medicine, U. of Cincinnati